AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400679-T1: [Translated] FIBER EXTRACTOR WITH ADJUSTABLE ANGLE OF AIR SHAFT AND STORAGE STRAP

Fibers from the card cylinder (3) are deposited in an airflow through a chute (2) on an air-permeable conveyor (11) to form a non-woven. The position of the chute side (4) together with the roller (5) can be adjusted. In addition, the side (7) together with the delivery edge (8) is also adjustable to control the distance for which fibers remain on the cylinder (3) after the last card segment (9). The chute (2) has an airflow splitter (6), which is also adjustable. The conveyor (11) runs in the opposite direction to the airflow and at an angle to it.
2012 Uniform Reporting System (URS) Tables for Kentucky

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Obtaining reliable information from minute amounts of RNA using cDNA microarrays

Background
          High density cDNA microarray technology provides a powerful tool to survey the activity of thousands of genes in normal and diseased cells, which helps us both to understand the molecular basis of the disease and to identify potential targets for therapeutic intervention. The promise of this technology has been hampered by the large amount of biological material required for the experiments (more than 50 μg of total RNA per array). We have modified an amplification procedure that requires only 1 μg of total RNA. Analyses of the results showed that most genes that were detected as expressed or differentially expressed using the regular protocol were also detected using the amplification protocol. In addition, many genes that were undetected or weakly detected using the regular protocol were clearly detected using the amplification protocol. We have carried out a series of confirmation studies by northern blotting, western blotting, and immunohistochemistry assays.
        
        
          Results
          Our results showed that most of the new information revealed by the amplification protocol represents real gene activity in the cells.
        
        
          Conclusion
          We have confirmed a powerful and consistent cDNA microarray procedure that can be used to study minute amounts of biological tissue.
Paediatric intensive care: out of commission

Problems with commissioning paediatric intensive care stem both from difficulties in recruitment and retention of nurses, and from incoherent or nonexistent national audit. Pyramidal career structures and patterns of remuneration that concentrate on administrative responsibility over clinical skills underlie the former, whereas poor audit conceals variations in both service quality and demand. Epidemiologically superior data are required if we are to solve commissioning problems. We need to know what happened to every child from a defined population receiving intensive care and whether a lack of resources means that some children are denied intensive care.
Compound 529777: 2-Hexanone, 6-(3,4-methylenedioxyphenyl)

Chemical compound data from PubChem database. IUPAC Name: 6-(1,3-benzodioxol-5-yl)hexan-2-one. Molecular Formula: C13H16O3. Molecular Weight: 220.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NF-κB DNA-binding activity in embryos responding to a teratogen, cyclophosphamide

Background
          The Rel/NF-κB transcription factors have been shown to regulate apoptosis in different cell types, acting as inducers or blockers in a stimuli- and cell type-dependent fashion. One of the Rel/NF-κB subunits, RelA, has been shown to be crucial for normal embryonic development, in which it functions in the embryonic liver as a protector against TNFα-induced physiological apoptosis. This study assesses whether NF-κB may be involved in the embryo's response to teratogens. Fot this, we evaluated how NF-KappaB DNA binding activity in embryonic organs demonstraiting differential sensitivity to a reference teratogen, cyclophosphamide, correlates with dysmorphic events induced by the teratogen at the cellular level (excessive apoptosis) and at the organ level (structural anomalies).
        
        
          Results
          The embryonic brain and liver were used as target organs. We observed that the Cyclophosphamide-induced excessive apoptosis in the brain, followed by the formation of severe craniofacial structural anomalies, was accompanied by suppression of NF-κB DNA-binding activity as well as by a significant and lasting increase in the activity of caspases 3 and 8. However, in the liver, in which cyclophosphamide induced transient apoptosis was not followed by dysmorphogenesis, no suppression of NF-κB DNA-binding activity was registered and the level of active caspases 3 and 8 was significantly lower than in the brain. It has also been observed that both the brain and liver became much more sensitive to the CP-induced teratogenic insult if the embryos were exposed to a combined treatment with the teratogen and sodium salicylate that suppressed NF-κB DNA-binding activity in these organs.
        
        
          Conclusion
          The results of this study demonstrate that suppression of NF-κB DNA-binding activity in embryos responding to the teratogenic insult may be associated with their decreased resistance to this insult. They also suggest that teratogens may suppress NF-κB DNA-binding activity in the embryonic tissues in an organ type- and dose-dependent fashion.
Compound 526798: 3-Hydroxy-stearic acid, methyl ester, 3-tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 3-[tert-butyl(dimethyl)silyl]oxyoctadecanoate. Molecular Formula: C25H52O3Si. Molecular Weight: 428.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Information Memorandum (IM-84-09)

This Information Memorandum (IM) establishes FY 1984 allotments for title IV-B, and procedures for applying for: (1) A state's share of funds available under title IV-B in FY 1984; (2) reallotted IV-B funds; and (3) Funds to be transferred from title IV-E-foster care.

Metadata-only record linking to the original dataset. Open original dataset below.
Global Tobacco Surveillance System (GTSS) - Global Adult Tobacco Survey (GATS)

2008-2017. Centers for Disease Control and Prevention (CDC).   Office on Smoking and Health (OSH) – Global Tobacco Surveillance System (GTSS) - Global Adult Tobacco Survey (GATS).    The Global Adult Tobacco Survey (GATS) is the global standard to systematically monitor adult tobacco use and track key tobacco control indicators. GATS is a nationally representative household survey of adults 15 years of age or older, using a standard protocol. It is intended to generate comparable data within and across countries. GATS enhances countries' capacity to design, implement and evaluate tobacco control interventions.
Compound 527599: 4-Penten-1-ol, dibromoacetate

Chemical compound data from PubChem database. IUPAC Name: pent-4-enyl 2,2-dibromoacetate. Molecular Formula: C7H10Br2O2. Molecular Weight: 285.96. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529345: 2-Acetyl-4-isopropylpyridine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-propan-2-ylpyridin-2-yl)ethanone. Molecular Formula: C10H13NO. Molecular Weight: 163.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526538: (4-Ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl) acetate

Chemical compound data from PubChem database. IUPAC Name: (4-ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl) acetate. Molecular Formula: C21H29NO7. Molecular Weight: 407.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527106: N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide

Chemical compound data from PubChem database. IUPAC Name: N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide. Molecular Formula: C18H17Cl2NO. Molecular Weight: 334.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Anti-cytokine therapy in chronic destructive arthritis

Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are considered to be master cytokines in chronic, destructive arthritis. Therapeutic approaches in rheumatoid arthritis (RA) patients have so far focused mainly on TNF, which is a major inflammatory mediator in RA and a potent inducer of IL-1; anti-TNF therapy shows great efficacy in RA patients. However, it is not effective in all patients, nor does it fully control the arthritic process in affected joints of good responders. Directed therapy for IL-1, with IL-1 receptor antagonist, mainly reduces erosions and is marginally anti-inflammatory. It is as yet unclear whether the limited effect is akin to the RA process or linked to suboptimal blocking of IL-1. Analysis of cytokine patterns in early synovial biopsies of RA patients reveals a marked heterogeneity, with variable staining of TNF and IL-1β, indicative of TNF-independent IL-1 production in at least some patients. Evidence for this pathway emerged from experimental arthritises in rodents, and is summarized in this review. If elements of the models apply to the arthritic process in RA patients, it is necessary to block IL-1β in addition to TNF.
Compound 527060: 1-Methyl-4-(5-methyl-1-methylenehex-4-enyl)-7-oxabicyclo[4.1.0]heptane

Chemical compound data from PubChem database. IUPAC Name: 1-methyl-4-(6-methylhepta-1,5-dien-2-yl)-7-oxabicyclo[4.1.0]heptane. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528935: Benzaldehyde, 2-hydroxy, 5-tert.-octyl, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: 1-[5-(2,4,4-trimethylpentan-2-yl)-2-trimethylsilyloxyphenyl]-N-trimethylsilyloxymethanimine. Molecular Formula: C21H39NO2Si2. Molecular Weight: 393.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400560-T1: [Translated] METHOD FOR PRODUCING 10.11 DIHYDRO 10 HYDROXY 5H-DIBENZ/B,F/AZEPINE-5-CARBONIC ACID AMIDE AND 10.11 DIHYDRO 10 OXO-5H-DIBENZ/B,F/AZEPINE-5 CARBONIC ACID AMIDE

Chemical patent from PubChem database. Patent Number: AT-E400560-T1. Title: Pharmaceutical Salt Forms. Filing Date: 2001-06-17. Inventors: Anderson, Robert, Davis, Linda. Abstract: Novel pharmaceutical salt forms are provided, exhibiting improved physicochemical properties including enhanced solubility, stability, and bioavailabi... IPC Classifications: C07H, A61K, A61P. This patent covers 14 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Use of intravenous antiarrhythmics to identify concealed Brugada syndrome

Cardiology has recently witnessed the production of an overwhelming amount of data through the advances made in genetics and molecular biology research. Understanding of genetics has tremendous potential to aid in the prevention, diagnosis and treatment of the majority of diseases. Despite the high level of publicity for research discoveries, clinicians have had difficulty in discriminating between what is still basic research and what can be applied to patients. The fact is that we still lack the technology to perform genetic testing in a time frame that is acceptable to clinicians. Meanwhile, then, the only option is to rely on clinical tests that can help us better stratify the individuals at risk for a disease. For example, Brugada syndrome has benefited tremendously from genetics and molecular biology since its initial description in 1992. Genetics will provide a more definitive diagnosis for the disease in the future. For the time being, though, research has shown that the administration of an intravenous class I antiarrhythmic is very useful in identifying patients with a concealed form of the disease.
The effects of 1α,25-dihydroxyvitamin D

The biologically active metabolite of vitamin D3, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], acts through vitamin D receptors, which were found in rheumatoid tissues in the present study. IL-1β-activated rheumatoid synovial fibroblasts and human articular chondrocytes were shown to respond differently to exposure to 1α,25(OH)2D3, which has different effects on the regulatory pathways of specific matrix metalloproteinases and prostaglandin E2.
State-Level Restrictions on Vaccine Mandates – All

: This dataset contains all vaccine mandate prohibitions that were issued as of ____, by 50 states, 5 territories, and the District of Columbia regardless of whether the law has been superseded by a subsequent law, postponed by subsequent law, or otherwise modified. State and territorial laws are collected from publicly available government websites and cataloged and coded in HHS Protect by one coder with one or more additional coders conducting quality assurance. 
Data were collected to determine when certain groups were prohibited from issuing vaccine mandates and to what groups those prohibitions applied. Data can be used to determine when states announced and began prohibiting for different groups from being required to be vaccinated. 
These data are derived from publicly available state and territorial laws and official policy documents found by the CDC, COVID-19 Mitigation Policy Analysis Unit, and the CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 1, 2020 through _____. These data will be updated as new laws are collected. Any orders not available through publicly accessible websites are not included in this dataset. Recommendations not included in a law are not included in these data. Effective and expiration dates were coded using only the date provided in the law. These data do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Children’s Bureau Discretionary Grant Reviewer Application Process

The Children's Bureau (CB) is seeking qualified subject-matter experts (SMEs) with relevant work experience to participate as grant peer reviewers.

CB provides discretionary funds competitively to state, tribal and local agencies, community organizations, and faith-based organizations to improve the safety, permanency and well-being of our nation’s children and families. We are seeking qualified SMEs to serve as reviewers for the competitive discretionary grant review process. As peer reviewers, you are vital to this process because you assist the federal government in awarding funds to only the most qualified applications.

Federal program officers will review profiles to identify SMEs whose expertise best matches the needs of a particular program. If your profile matches those needs closely then you may be contacted to serve as a peer reviewer. Reviewers typically work in panels of 4 and read, score, and evaluate the strengths and weaknesses of submitted applications.

If you are interested in serving as a grant reviewer, please go to https://rrm.grantsolutions.gov/AgencyPortal/cb.aspx
  
  

 to create your profile. You will be asked to upload your résumé or curriculum vita (CV) in addition to responding to a few questions and detailing your areas of expertise, experience, and education. You must upload a résumé or CV in order to be considered to serve as a grant reviewer. Serving as a peer reviewer is an equal opportunity experience. Non-federally employed subject matter experts (SMEs) may receive monetary compensation for their participation on a review panel.

For more information on Children’s Bureau grant reviews, please contact CBReview@grantreview.org.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530287: 1-Butene, 2,4-bis-trimethylsilyl

Chemical compound data from PubChem database. IUPAC Name: trimethyl(3-trimethylsilylbut-3-enyl)silane. Molecular Formula: C10H24Si2. Molecular Weight: 200.47. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Inpatient Discharges (SPARCS De-Identified): Potentially Preventable Complication (PPC) Individual Rates by Hospital: Beginning 2013

The dataset shows each of the 66 individual Potentially Preventable Complication (PPC) measures, providing observed and risk-adjusted rates for all payer discharges by hospital and statewide, beginning in 2013.

Potentially Preventable Complications (PPC), obtained from software created by 3M Health Information Systems, are defined as harmful events or negative outcomes that develop or occur during hospitalization and may result from processes of care and treatment rather than from natural progression of the underlying illness. 

The PPCs were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data.
Patent AT-E39964-T1: [Translated] PROCESS FOR MANUFACTURING SECURITY KEYS WITH DIFFERENT LOCKING POSSIBILITIES.

1. Method of making safety keys (10) with locking possibilities differing from each other, wherein spring-loaded pin tumblers are mounted in the locks in bores which run radially, which tumblers can be set by a safety key (10) to release for rotation the cylindrical-shaped core, which key is introduced into the key channel of the cylindrical-shaped core and which by means of bores (11) sets the correct displacement position of the rows of pin tumblers, wherein bore patterns are provided with conventional bore depressions (9) and also with bores (a-k) which differ as regards the number and/or form of the control surfaces, characterized in that in the following sequence a) bore patterns (A-E) are produced, which differ from each other, with each bore pattern (A-E) having the same number of bore sites (5) and with the position of the bore sites (5) being different in each bore pattern (A-E), b) in each bore pattern a given number of distinguished bore sites (14, 15) is varied as regards their position, this number being at least one, and c) each distinguished bore site (14, 15) is further varied as regards a given number of bore forms (a-k) which differ from each other.
Program Instruction (PI-06-04)

This Program Instruction (PI) provides instruction to tribes on the June 30, 2006 submission of the Annual Progress and Services Report (APSR) as required under Title IV-B of the Social Security Act, including the submission of the CFS-101, Parts I and II, Annual Budget Request and Annual Summary of Child and Family Services.

Metadata-only record linking to the original dataset. Open original dataset below.
Table 15. Cigarette Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past month cigarette use by those aged 12 to 20 in State and substate regions.
The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)

Paired synovial tissue samples were obtained from both clinically uninvolved (CU) and clinically involved (CI) knee joints of eight rheumatoid arthritis (RA) patients. In addition, biopsies were taken from five control subjects. We observed the expression of the chemokines CXCL8, CXCL9, CXCL10, CCL2 and CCL4 in CI and CU joints of RA patients. In particular, CXCL8 protein levels were specifically increased in CI joints compared with CU joints, which was confirmed by immunohistochemistry and in situ hybridization.
2015 National Directory of Drug and Alcohol Abuse Treatment Facilities

This publication is a directory with a listing of Federal, State,and local government facilities and private facilities that provide substance abuse treatment services. It includes treatment facilities that (1) are licensed, certified, or otherwise approved for inclusion in the Directory by their State substance abuse agencies, and (2) responded to the 2014 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this Directory was provided by that facility in response to the 2014 N-SSATS. N-SSATS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA). The Directory is ordered alphabetically by State, by city within each State, and by facility name within each city. This Directory includes All US States and Territories.
Patent AT-E400705-T1: [Translated] TEMPORARY MARKING MATERIAL AND ROAD MARKING DEVICE

A temporary marking material comprises a thermally-expansible layer containing a binder, a pigment and thermally-expansible microballs, and a pavement marker comprises the temporary marking material. Both the temporary marking material and the pavement maker hardly peel off or move during the use, and when they become unnecessary, they can be easily peeled off by heating from the structure in a short time by virtue of the expanded microballs. When the temporary marking material is in practical use, the thermally-expansible layer is disposed on the surface of a structure. The pavement marker is disposed on the pavement as part of a surface of the structure.
Compound 525456: 3-Propyl-2,4-dithiahexane

Chemical compound data from PubChem database. IUPAC Name: 1-ethylsulfanyl-1-methylsulfanylbutane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400252-T1: [Translated] PHARMACEUTICAL SOLID DISPERSIONS

A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100 DEG C measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50 DEG C at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%. <IMAGE>